A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies

The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.

Trial Details

NCT ID
NCT06971523
Phase
PHASE1 / PHASE2
Sponsor
CytosinLab Therapeutics Co., Ltd.
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • CTS3497
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723

Key Eligibility Criteria

  • ≥ 18 years of age at the signing of ICF.
  • Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors who cannot be treated surgically and have faile…
  • MTAP deficiency is confirmed by IHC or NGS.
  • At least one evaluable tumor lesion at screening for patients in escalation part, and at least one measurable tumor lesion for patients in expansio…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →